By using this site, you agree to the Privacy Policy and Terms of Use.
Accept

News Junction

Notification Show More
Font ResizerAa
  • Home
  • World News
    World NewsShow More
    Pony.ai teams up with Tencent for robotaxi services on WeChat, other apps
    Pony.ai teams up with Tencent for robotaxi services on WeChat, other apps
    April 26, 2025
    Trump, China trade conflicting statements on trade talks, raising confusion – National
    Trump, China trade conflicting statements on trade talks, raising confusion – National
    April 26, 2025
    Royal Caribbean Is Temporarily Rerouting Cruises That Depart From 3 Florida Cities—Here’s Why
    Royal Caribbean Is Temporarily Rerouting Cruises That Depart From 3 Florida Cities—Here’s Why
    April 26, 2025
    How much foreign aid is spent domestically rather than overseas?
    How much foreign aid is spent domestically rather than overseas?
    April 26, 2025
    Pakistan and India border closure separates families
    Pakistan and India border closure separates families
    April 26, 2025
  • Business
    BusinessShow More
    Ukraine blows up bridges to consolidate its positions in Russia
    Ukraine blows up bridges to consolidate its positions in Russia
    August 18, 2024
    Commentary: AI phones from Google and Apple will erode trust in everything
    Commentary: AI phones from Google and Apple will erode trust in everything
    August 18, 2024
    The most famous Indian Dishes – Insights Success
    The most famous Indian Dishes – Insights Success
    August 18, 2024
    Life on the road as a female long rides cyclist
    Life on the road as a female long rides cyclist
    August 18, 2024
    UK inflation rises to 2.2%
    UK inflation rises to 2.2%
    August 18, 2024
  • Cryptocurrency
    CryptocurrencyShow More
    BTC, ETH, XRP, BNB, SOL, DOGE, ADA, SUI, LINK, AVAX
    BTC, ETH, XRP, BNB, SOL, DOGE, ADA, SUI, LINK, AVAX
    April 26, 2025
    SUI’s 73% weekly price gains top crypto market — New price record in reach?
    SUI’s 73% weekly price gains top crypto market — New price record in reach?
    April 26, 2025
    BlackRock, five others account for 88% of all tokenized treasury issuance
    BlackRock, five others account for 88% of all tokenized treasury issuance
    April 26, 2025
    Traders still offloading TRUMP holdings after dinner announcement — Nansen
    Traders still offloading TRUMP holdings after dinner announcement — Nansen
    April 26, 2025
    Ronin Bridge migrates to Chainlink cross-chain interoperability protocol
    Ronin Bridge migrates to Chainlink cross-chain interoperability protocol
    April 26, 2025
  • Technology
    TechnologyShow More
    How to Improve Your Spotify Recommendations
    How to Improve Your Spotify Recommendations
    August 18, 2024
    X says it’s closing operations in Brazil
    X says it’s closing operations in Brazil
    August 18, 2024
    Supermoon set to rise: Top tips for amateur photographers | Science & Tech News
    Supermoon set to rise: Top tips for amateur photographers | Science & Tech News
    August 18, 2024
    Scientists Want to See Videos of Your Cat for a New Study
    Scientists Want to See Videos of Your Cat for a New Study
    August 18, 2024
    OpenAI’s new voice mode let me talk with my phone, not to it
    OpenAI’s new voice mode let me talk with my phone, not to it
    August 18, 2024
  • Entertainment
  • Sports News
  • People
  • Trend
Reading: Obesity drug Wegovy’s trial result could ‘open up’ health insurance access
Share
Font ResizerAa

News Junction

  • World News
  • Business
  • Technology
  • Cryptocurrency
  • Trend
  • Entertainment
Search
  • Recent Headlines in Entertainment, World News, and Cryptocurrency – NewsJunction
  • World News
  • Business
  • Cryptocurrency
  • Technology
  • Entertainment
  • Sports News
  • People
  • Trend
Have an existing account? Sign In
Follow US
News Junction > Blog > World News > Obesity drug Wegovy’s trial result could ‘open up’ health insurance access
Obesity drug Wegovy’s trial result could ‘open up’ health insurance access
World News

Obesity drug Wegovy’s trial result could ‘open up’ health insurance access

Published August 9, 2023
Share
8 Min Read
SHARE

Contents
Big market, little competitionSupply constraints weigh

A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023.

Jim Vondruska | Reuters

LONDON — Popular weight-loss drug Wegovy could be made available under more health insurance schemes, after the results of a late-stage trial pointed to the drug’s efficacy in reducing major cardiovascular events, analysts said on Wednesday.

The findings of Novo Nordisk‘s closely watched “SELECT” trial exceeded expectations on Tuesday, indicating that Wegovy lowered the risk of major cardiovascular events such as heart attacks or strokes by 20%, compared with a placebo.

The Danish pharmaceutical company said it will now seek permission from U.S. and European regulators to add cardiovascular benefits to the drug label.

Peter Verdult, managing director and pharmaceuticals analyst at Citi, on Wednesday said that the trial conclusions could transform the medication from an apparent vanity drug to one that health insurers are willing to fund.

“Data like this is going to fuel, I think, patients’ demand for the drug, physicians’ willingness to prescribe, and, most importantly, payers’ willingness to reimburse,” he told CNBC’s “Street Signs.”

Until now, some health insurers have been reluctant to cover the drug, given its high costs and a lack of data around its underlying health benefits. Wegovy has a U.S. list price of $1,350, while it retails for around 170 and 300 euros ($190-$330) per month in the parts of Europe where it is available.

But the results of the latest trial data could change that. The double-blind trial began almost five years ago and involved more than 17,600 adults with established cardiovascular disease who were overweight or suffered from obesity, but had no prior history of diabetes.

“The willingness to reimburse obesity drugs is improving — and that’s happening even before yesterday’s SELECT,” Verdult said, citing certain reimbursements available in the U.S. and the U.K. “SELECT data is not going to hurt that trajectory. It is going to, I think, further open up access.”

Commenting on the results on Tuesday, Novo Nordisk’s executive vice president for development, Martin Holst Lange, said the drug “has the potential to change how obesity is regarded and treated.”

U.S. pharmaceutical company Eli Lilly, which produces rival obesity drug Mounjaro, said in its earnings call of Tuesday that the trial results could provide assurance to some insurers, though it is unlikely to lead to widespread coverage in the near term.

“Do I think most payers will adopt [obesity drugs] overnight because of the SELECT trial? I don’t think so,” Michael Mason, senior vice president at Eli Lily and president of Lilly Diabetes, said. He noted that more “real-world evidence” is needed to support payer decisions, adding that the company is also investing in trials for its own weight-loss drug.

According to the World Health Organization, global obesity rates have almost tripled over the past decade. It is currently estimated that 1 billion people are clinically obese, of whom around 650 million are adults, 340 million are adolescents and 39 million are children. Cardiovascular diseases (CVDs), meanwhile, are the leading cause of death globally, claiming an estimated 17.9 million lives each year.

Big market, little competition

The weight-loss drug industry is estimated to be worth as much as $200 billion within the next decade, according to Barclays forecasts announced in April.

Novo Nordisk shares soared by 17% following the release of the trial results on Tuesday.

The company — whose share price has risen nearly 300% over the past five years — could now be on course to dethrone luxury goods giant LVMH as Europe’s most valuable firm by market capitalization.

“We expect gains in the shares to largely hold, as we view this as a big step forward de-risking the obesity market globally over the longer term,” Barclays said in a research note Tuesday.

It’s a real tall order [for competitors] to come in and knock these giants off their perch.

Peter Verdult

pharmaceuticals analyst at Citi

Verdult said Wednesday that the gains were likely to endure, given the current lack of competition in the market. Shares of the stock were down 1.5% by 12:00 p.m. London time.

“Lilly and Novo are entrenched in the world of diabetes commercially. And they now, as we saw yesterday with SELECT, have outcomes data to further buttress this sort of clinical profile,” he said.

“It’s a real tall order [for competitors] to come in and knock these giants off their perch,” he continued.

“Unless, heaven forbid, there’s some unexpected side effect that emerges, it’s very difficult to see Novo and Lily being pushed away.”

Supply constraints weigh

Some health concerns have indeed emerged around the so-called ‘miracle’ weight loss drugs.

The European Markets Authority last month launched a review of a number of drugs used to treat obesity and diabetes amid reports that some patients had experienced thoughts of suicide or self-harm. Novo Nordisk and Eli Lilly are also facing a lawsuit over complaints that their drugs caused stomach paralysis.

Verdult said such reports were to be expected given the amount of media attention around the drugs. But he added that he believed the drugs’ current risk-benefit profile is “definitely positive rather than negative.”

A more immediate hurdle for the company, however, may be keeping up with surging demand.

'Miracle' drugs could remake the weight loss industry

Novo Nordisk and Eli Lily have already warned of supply constraints led by a spike in orders, including from non-obese people, and have urged physicians to limit prescriptions to patients with medical needs.

“The increased demand for this drug will exacerbate the shortages of Wegovy and Ozempic, which may last way into 2024,” Zhyar Said, healthcare analyst at pharmaceutical market research firm Citeline, told CNBC by email.

Eli Lilly said Tuesday in its second-quarter earnings announcement that it continues to expect “intermittent delays fulfilling orders of certain Mounjaro doses given significant demand.”

Novo Nordisk told CNBC that it could not comment on the shortages, as it remains in a quiet period ahead of its earnings release on Thursday.

The company said in May that it was “ramping up supply every day” and employing new contractors to increase its output.

Verdult noted it could be some time before the shortfall eases, “It’s not going to be a quick fix.”

Disclosure: Barclays is an investor in Novo Nordisk.

#Obesity #drug #Wegovys #trial #result #open #health #insurance #access

TAGGED:accessBiotech and PharmaceuticalsBiotechnologyBusinessbusiness newsdrughealthHealth care industryinsuranceLVMH Moet Hennessy Louis Vuitton SENovo Nordisk A/SObesityOpenPharmaceuticalsresulttrialWegovys
Share This Article
Facebook Twitter Pinterest Whatsapp Whatsapp LinkedIn Email Copy Link Print
Share
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Previous Article Gatwick strikes: Holidaymakers warned of ‘severe disruption’ as fresh walkouts announced Gatwick strikes: Holidaymakers warned of ‘severe disruption’ as fresh walkouts announced
Next Article Google Says It Will Scrape Websites for AI Unless Forced Not To Google Says It Will Scrape Websites for AI Unless Forced Not To

You Might Also Like

India inflation and industrial data in focus
World News

India inflation and industrial data in focus

August 12, 2024
Deutsche Bank smashes profit estimates and boosts shareholder returns
World News

Deutsche Bank smashes profit estimates and boosts shareholder returns

February 1, 2024
Protesters and security forces clash in Senegal over election delay | Elections News
World News

Protesters and security forces clash in Senegal over election delay | Elections News

February 10, 2024
House GOP releases impeachment articles in bid to oust Homeland Security’s Mayorkas over the border
World News

House GOP releases impeachment articles in bid to oust Homeland Security’s Mayorkas over the border

January 28, 2024

About Us

NEWS JUNCTION (NewsJunction.xyz) Your trusted destination for global news. Stay informed with our timely and accurate reporting on diverse topics, including politics, technology, science, entertainment, sports, and more. Count on us for unbiased and reliable updates at your fingertips.

Quick Link

  • About
  • Disclaimer
  • Privacy Policy
  • Terms of Use
  • Contact

Top Categories

  • World News
  • Business
  • Technology
  • Entertainment
  • Cryptocurrency
  • Sports News
  • Trend
  • People

Subscribe

Subscribe to our newsletter to get our newest articles instantly!

    © 2023 News Junction.
    • Blog
    • Advertise
    • Contact
    Welcome Back!

    Sign in to your account

    Username or Email Address
    Password

    Lost your password?